Health-care technology companies are making headway by leading the way in innovation to save and enhance the quality of lives.
Freehold, New Jersey-based Medifirst Solutions Inc. (OTC:MFST) came out with a company update Wednesday.
The provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, recently announced a possible new expansion and direction for its Time Machine Therapeutic Laser. It’s a device being used for the application of Photobiomodulation (PBM) to treat a side effect of cancer therapy called Oral Mucositis.
Medifirst says it’s engaged its FDA consulting firm to assist in preparing and submitting a pre-510(k) submission to the FDA for 510(k) indication for treating Oral Mucositis with its FDA 510(k) cleared hand-held Infrared 810nm Laser.
According to industry statistics, Oral Mucositis affects about 400,000 patients annually in the United States, affecting their cheeks, lips, gums, inner cavity and tonsillary region. Treatment options today are rather limited. Patients are usually given pain medication and/or antiseptic mouthwash.
Beyond that, there's not much doctors can do for the painful condition that, at advanced stages, can inhibit a patient's ability to eat and speak.
MFST shares rocketed 6.4% late Wednesday to 2.65 cents, on volume of 1.1 million shares.
